1-7 of 7
Lowell Hart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward Faber, Jeffrey Matous, MD, Lowell Hart, MD, Joseph R. Mace, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4530.
https://doi.org/10.1182/blood.V128.22.4530.4530
Published: 2016
Journal Articles

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Jeffrey A Zonder, MD, Saad Usmani, Emma C. Scott, MD, Craig C. Hofmeister, MD, Nikoletta Lendvai, MDPhD, Jesus G. Berdeja, MD, Larry D. Anderson, Jr., MD PhD, Parameswaran Hari, MBBS, MD MRCP, Seema Singhal, MD, Gregory Orloff, MD, Michael Craig, MD, Jason Valent, MD, Wes Lee, Lowell Hart, J Hrom, Stephano Tarantolo, Edward Faber, DO, Gary J Schiller, MD, Jennifer Schreiber, BS, Colleen Oliver, MSc, Selena A Rush, BS, Brian Tunquist, Mieke Ptaszynski, Noopur S. Raje, MD
Journal: Blood
Blood (2015) 126 (23): 728.
https://doi.org/10.1182/blood.V126.23.728.728
Published: 2015
Journal Articles

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Jesus Berdeja, MD, Michael Savona, MD, Joseph R Mace, MD, Lowell Hart, MD, James Essell, MD, Rami Owera, MD, Edward Arrowsmith, MD, MPH, Ian Flinn, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1937.
https://doi.org/10.1182/blood.V122.21.1937.1937
Published: 2013
Journal Articles

Phase I/II Study of Panobinostat and Carfilzomib in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Interim Phase I Safety Analysis

Jesus G. Berdeja, MD, Lowell Hart, MD, Ruth Lamar, MD, Patrick Murphy, MD, Susan Morgan, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4048.
https://doi.org/10.1182/blood.V120.21.4048.4048
Published: 2012
Journal Articles

Rituximab Therapy after Response to R-CHOP Induction Therapy for Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma (NHL): Clinical Outcomes and Pharmacokinetics (PK)

Louis Fehrenbacher, MD, Jonathan A. Polikoff, MD, Robert Hermann, MD, Haresh Jhangiani, MD, Jean Bjerke, MD, David Loeck, MD, Lowell Hart
Journal: Blood
Blood (2007) 110 (11): 1295.
https://doi.org/10.1182/blood.V110.11.1295.1295
Published: 2007
Journal Articles

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, Martha Glenn, Stephanie A. Gregory, Charles Holladay, Anthony Boral, Tracy Zhang, André Goy
Journal: Blood
Blood (2005) 106 (11): 17.
https://doi.org/10.1182/blood.V106.11.17.17
Published: 2005
Journal Articles

Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Advanced Stage Indolent Non-Hodgkin’s Lymphoma (NHL); Initial Results of Induction Therapy in a Phase II Study.

Jane E. Huang, MD, Lowell Hart, MD, Jonathon Polikoff, MD, Virginia Langmuir, MD, Fan Zhang, Louis Fehrenbacher, MD
Journal: Blood
Blood (2004) 104 (11): 4615.
https://doi.org/10.1182/blood.V104.11.4615.4615
Published: 2004